AndhraNews.net
Home » Business News » 2011 » May » May 6, 2011

Cornerstone Therapeutics to Host First Quarter 2011 Conference Call


May 6, 2011 - Cary, NC

Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that it will host a conference call at 8:30 a.m. ET on Thursday, May 12, 2011, to discuss its financial results for the first quarter ended March 31, 2011. Financial results are expected to be released on Thursday, May 12, 2011, before the open of the U.S. financial markets.

To participate in the live conference call, please dial 800-561-2813 (U.S. callers) or 617-614-3529 (international callers), and provide passcode 83824284. A live webcast of the call will also be available through the Investor Relations section of the Company's website. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The conference call and the webcast will be archived for 30 days. The telephone replay of the call will be available at 11:30 a.m. ET on May 12, 2011 by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 44878149.

About Cornerstone Therapeutics
Cornerstone Therapeutics Inc. (NASDAQ: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the respiratory and related markets. Key elements of the Company's strategy are to leverage commercial capabilities by promoting respiratory and related products to high prescribing physicians through its respiratory sales force and to hospital-based healthcare professionals through its hospital sales force; acquire rights to existing patent- or trade secret-protected, branded products, which can be promoted through the same channels to generate on-going high-value earnings streams; advance its development projects and further build a robust pipeline; and generate revenues by marketing approved generic products through its wholly owned subsidiary, Aristos Pharmaceuticals, Inc.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements, our ability to enter into strategic licensing, product acquisition, collaboration or co-promotion transactions on favorable terms, if at all, and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 3, 2011 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, and these statements should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.

Contacts
Investor Relations Contacts:
Westwicke Partners
John Woolford
+1-443-213-0506
Email Contact

Westwicke Partners
Stefan Loren, Ph.D.
+1-443-213-0507
Email Contact

Media Relations Contact:
Fleishman-Hillard
Andrea Moody
+1-919-457-0743
Email Contact

MarketWire

Comment on this story

Share